# AMN Healthcare Services Inc: Form 10-Q for the period ended Sep 30, 2019

- Company: [AMN Healthcare Services Inc](/companies/amn.md) (CIK 1142750)
- Form: 10-Q
- Filed: 2019-11-04
- Accepted by EDGAR: Nov 4, 2019, 17:04 ET
- Period: 2019-09-30
- Accession: 0001142750-19-000035
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1142750/000114275019000035/amn-20190930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1142750/000114275019000035/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $567.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $1.64bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $377.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $1.09bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $190.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $546.3m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-30 | $133.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-30 | $374.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $39.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | $129.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $7.8m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $19.6m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $8.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $23.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | $23.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | $86.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.49 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | $1.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | $0.50 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | $1.85 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 47,607,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 47,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $146.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $24.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2019-01-01 to 2019-09-30 | $18.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-09-30 | $40.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $506.9m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $1.86bn | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $343.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $1.16bn | us-gaap:Liabilities |
| Shareholders' equity | at 2019-09-30 | $705.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 49,117 characters.

### of Operations

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto and other financial information included elsewhere herein and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on February 21, 2019 (“2018 Annual Report”). Certain statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are “forward-looking statements.” See “Special Note Regarding Forward-Looking Statements.” We undertake no obligation to update the forward-looking statements in this Quarterly Report. References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries.

### Overview of Our Business

We provide healthcare workforce solutions and staffing services to healthcare facilities across the nation. As an innovative workforce solutions partner, our managed services programs, or “MSP,” vendor management systems, or “VMS,” workforce consulting services, predictive modeling, staff scheduling, revenue cycle solutions and the placement of physicians, nurses, allied healthcare professionals and healthcare leaders into temporary and permanent positions enable our clients to successfully reduce staffing complexity, increase efficiency and lead their organizations within the rapidly evolving healthcare environment.

We conduct business through three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. For the three months ended September 30, 2019, we recorded revenue of $567.6 million, as compared to $526.8 million for the same period last year. For the nine months ended September 30, 2019, we recorded revenue of $1,635.2 million, as compared to $1,607.4 million for the same period last year.

Nurse and allied solutions segment revenue comprised 63% and 61% of total consolidated revenue for the nine months ended September 30, 2019 and 2018, respectively. Through our nurse and allied solutions segment, we provide hospitals and other healthcare facilities with a comprehensive managed services solution in which we manage and staff all of the temporary nursing and allied staffing needs of a client and traditional clinical staffing solutions of variable assignment lengths.

Locum tenens solutions segment revenue comprised 15% and 19% of total consolidated revenue for the nine months ended September 30, 2019 and 2018, respectively. Through our locum tenens solutions segment, we provide a comprehensive managed services solution in which we manage all of the locum tenens needs of a client and place physicians of all specialties, as well as dentists and advanced practice providers, with clients on a temporary basis as independent contractors. These locum tenens providers are used by our clients to fill temporary vacancies created by vacation and leave schedules and to bridge the gap while they seek permanent candidates or explore expansion. Our locum tenens clients represent a diverse group of healthcare organizations throughout the United States, including hospitals, health systems, medical groups, occupational medical clinics, psychiatric facilities, government institutions, and insurance entities. The professionals we place are recruited nationwide and are typically placed on contracts with assignment lengths ranging from a few days to one year.

Other workforce solutions segment revenue comprised 22% and 20% of total consolidated revenue for the nine months ended September 30, 2019 and 2018, respectively. Through our other workforce solutions segment, we provide hospitals and other healthcare facilities with a range of workforce solutions, including: (1) identifying and recruiting physicians and healthcare leaders for permanent placement, (2) placing interim leaders and executives across all healthcare settings, (3) a software-as-a-service (“SaaS”) VMS through which our clients can manage their temporary staffing needs, (4) RPO services that leverage our expertise and support systems to replace or complement a client’s existing internal recruitment function for permanent placement needs, (5) an education program that provides custom healthcare education, research, professional practice tools, and professional development services, (6) revenue cycle solutions and related consulting services, (7)

workforce optimization services that include consulting, data analytics, predictive modeling, and SaaS-based scheduling technology, and (8) credentialing services.

As part of our long-term growth strategy to add value for our clients, healthcare professionals, and shareholders, on June 14, 2019, January 30, 2019, April 9, 2018 and April 6, 2018, we acquired Advanced, Silversheet, MedPartners HIM (“MedPartners”), and Phillips DiPisa and Leaders For Today (“PDA” and “LFT”), respectively. Advanced is a national healthcare staffing company that specializes in placing therapists and nurses across multiple settings, including hospitals, schools, clinics, skilled nursing facilities, and home health. Silversheet provides innovative credentialing software solutions to clinicians and healthcare enterprises. MedPartners provides revenue cycle solutions, including case management, clinical documentation improvement, medical coding and registry services to hospitals and physician medical groups nationwide. PDA and LFT offer a range of leadership staffing and permanent placement solutions for the healthcare industry. See additional information in the accompanying Note (2), “Acquisitions.”

### Recent Trends

Demand for our temporary and permanent placement staffing services is driven in part by U.S. economic and labor trends. The U.S. Bureau of Labor Statistics’ survey data reflects near record levels of healthcare job openings and quits. We view this data, along with a nearly 20-year-low unemployment rate and continued economic growth as positive trends for the healthcare staffing industry. These positive macro economic and labor trends have created a highly competitive labor market for clinicians and our clinician supply, particularly in nursing, has not kept pace with growth in client demand.

The consolidation within the healthcare industry is creating larger, more sophisticated and complex health systems that we believe has elevated the need for strategic workforce solutions capable of partnering to solve their recruiting, staffing and workforce optimization requirements. Given the increasing need for partners capable of offering a comprehensive workforce solution, we continue to see the benefits of our workforce solutions strategy, particularly with our MSPs. As a result of our ongoing focus on these strategic MSP relationships, the percentage of our staffing revenue derived from our MSP clients continues to increase, and we believe these strategic, longer-term relationships will continue to comprise a greater proportion of revenue in our staffing businesses.

In our nurse and allied solutions segment, overall demand is strong and at the highest levels seen since 2016. However, placement activity has been unfavorably impacted by fewer contingent nurse staffing needs from a large client. Additionally, a tight labor market and modest growth in bill rates is also impacting our ability to sufficiently recruit the nurses to meet the increased demand. Our allied staffing business continues to have strong overall demand resulting in steady organic revenue growth. However, we have recently experienced a decline in demand for therapists from our skilled nursing facility clients that is resulting from recently implemented Medicare reimbursement changes. The access to additional supply of nurse and allied healthcare professionals from the Advanced acquisition has helped us better address our client’s staffing demands.

The demand environment for locum tenens is also generally favorable, although demand for hospitalists and emergency room physicians has significantly declined over the past 12 months. Our locum tenens business has stabilized after disruption resulting from process and technology changes made during 2018, and recruiter productivity continues to improve.

In our other workforce solutions segment, better demand and placements in the interim leadership and physician permanent placement divisions and growth in technology workforce solutions are driving improved segment performance and our profitability on a consolidated basis. Since experiencing a decline in our revenue cycle solutions revenue in recent quarters, revenue for this division has seen signs of stabilization due in part to growing opportunities to serve our MSP customers.

### Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with United States generally accepted accounting principles (“U.S. GAAP”) requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to intangible assets purchased in a business combination, asset impairments, accruals for self-insurance, compensation and related benefits, accounts receivable, contingencies and litigation, earn-out liabilities, and income taxes. We base these estimates on the information that is currently available to us and on various other assumptions that we believe are reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions. If these estimates differ significantly from actual results, our consolidated financial statements and future results of operations may be materially impacted. There have been no material changes in our critical accounting policies and estimates, other than the adoption of the Accounting Standards Update (“ASU”) 2016-02 described in Item 1. Condensed Consolidated Financial Statements—Note 1, “Basis of Presentation,” as compared to the critical accounting policies and estimates described in our 2018 Annual Report.

### Results of Operations

The following table sets forth, for the periods indicated, selected unaudited condensed consolidated statements of operations data as a percentage of revenue. Our results of operations include three reportable segments: (1) nurse and allied solutions, (2) locum tenens solutions, and (3) other workforce solutions. The PDA, LFT, MedPartners, Silversheet and Advanced acquisitions impact the comparability of the results between the three and nine months ended September 30, 2019 and 2018 depending on the timing of the applicable acquisition. Our historical results are not necessarily indicative of our future results of operations.

*Unaudited Condensed Consolidated Statements of Operations:*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of revenue | 66.5 | 66.8 | 66.6 | 67.4 |
| Gross profit | 33.5 | 33.2 | 33.4 | 32.6 |
| Selling, general and administrative | 23.5 | 23.0 | 22.9 | 21.2 |
| Depreciation and amortization | 3.0 | 2.1 | 2.6 | 1.9 |
| Income from operations | 7.0 | 8.1 | 7.9 | 9.5 |
| Interest expense, net, and other | 1.4 | 0.9 | 1.1 | 1.0 |
| Income before income taxes | 5.6 | 7.2 | 6.8 | 8.5 |
| Income tax expense | 1.5 | 1.9 | 1.5 | 1.9 |
| Net income | 4.1% | 5.3% | 5.3% | 6.6% |

### Comparison of Results for the Three Months Ended September 30, 2019 to the Three Months Ended September 30, 2018

***Revenue.*** Revenue increased 8% to $567.6 million for the three months ended September 30, 2019 from $526.8 million for the same period in 2018, primarily attributable to additional revenue of $37.0 million from our Silversheet and Advanced acquisitions and higher organic revenue in our nurse and allied solutions segment, partially offset by lower revenue in our locum tenens solutions segment. Excluding the additional revenue from acquisitions, revenue increased 1%.

Nurse and allied solutions segment revenue increased 18% to $362.5 million for the three months ended September 30, 2019 from $306.3 million for the same period in 2018. The $56.2 million increase was primarily attributable to $36.6 million of revenue in connection with the Advanced acquisition, a 2% increase in the average number of healthcare professionals on assignment, and a 2% increase in the average bill rate during the during the three months ended September 30, 2019.

Locum tenens solutions segment revenue decreased 17% to $84.2 million for the three months ended September 30, 2019 from $101.1 million for the same period in 2018. The $16.9 million decrease was primarily attributable to a 15% decrease in the number of days filled and a 2% decrease in the revenue per day filled during the three months ended September 30, 2019.

Other workforce solutions segment revenue increased 1% to $120.9 million for the three months ended September 30, 2019 from $119.4 million for the same period in 2018. The $1.5 million increase was primarily attributable to growth in our interim leadership, permanent placement, recruitment process outsourcing, and VMS businesses, partially offset by a decline in our revenue cycle solutions business during the three months ended September 30, 2019.

***Gross Profit.*** Gross profit increased 8% to $190.0 million for the three months ended September 30, 2019 from $175.1 million for the same period in 2018, representing gross margins of 33.5% and 33.2%, respectively. The gross margin for the three months ended September 30, 2019 was positively impacted by a higher gross margin in our nurse and allied solutions segment, driven by a higher labor disruption margin and partially offset by higher traveler housing costs, and higher other workforce solutions gross margin. These positive factors were partially offset by a lower margin in our locum tenens solutions segment and an unfavorable segment mix shift. Gross margin by reportable segment for the three months ended September 30, 2019 and 2018 was 27.9% and 27.4% for nurse and allied solutions, 27.5% and 28.4% for locum tenens solutions, and 54.3% and 52.4% for other workforce solutions, respectively. The year-over-year gross margin decline in the locum tenens solutions segment was driven by lower perm conversion fees.

***Selling, General and Administrative Expenses.*** Selling, general and administrative (“SG&A”) expenses were $133.2 million, representing 23.5% of revenue, for the three months ended September 30, 2019, as compared to $121.2 million, representing 23.0% of revenue, for the same period in 2018. The increase in SG&A expenses was primarily due to $6.8 million of additional SG&A expenses from the Silversheet and Advanced acquisitions, a $10.1 million increase related to acquisition, integration, changes in the fair value of earn-out liabilities from acquisitions, and extraordinary legal expenses, higher employee compensation expenses, and other expenses associated with our revenue growth. The increase was partially offset by a $12.1 million increase in legal accruals during the three months ended September 30, 2018. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

|  | (In Thousands) Three Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Nurse and allied solutions | $53,673 | $41,643 |
| Locum tenens solutions | 16,998 | 17,762 |
| Other workforce solutions | 37,854 | 33,575 |
| Unallocated corporate overhead | 21,857 | 26,427 |
| Share-based compensation | 2,825 | 1,809 |
|  | $133,207 | $121,216 |

***Depreciation and Amortization Expenses.*** Amortization expense increased 70% to $11.4 million for the three months ended September 30, 2019 from $6.7 million for the same period in 2018, primarily attributable to additional amortization expenses related to the intangible assets acquired in the Silversheet and Advanced acquisitions and the shortened useful life of the tradename intangible asset acquired in the MedPartners acquisition. Depreciation expense increased 24% to $5.7 million for the three months ended September 30, 2019 from $4.6 million for the same period in 2018, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing front and back office information technology initiatives.

***Interest Expense, Net, and Other.*** Interest expense, net, and other, was $7.8 million during the three months ended September 30, 2019 as compared to $4.6 million for the same period in 2018. The increase is primarily due to a higher average debt outstanding balance for the three months ended September 30, 2019, which resulted from borrowings used to finance the Silversheet and Advanced acquisitions, and a $1.4 million gain related to the change in fair value of an equity investment during the three months ended September 30, 2018. The overall increase is partially offset by a higher income from restricted investments related to our captive insurance company for the three months ended September 30, 2019.

***Income Tax Expense.*** Income tax expense was $8.4 million for the three months ended September 30, 2019 as compared to $10.1 million for the same period in 2018, reflecting effective income tax rates of 26% and 27% for the three months ended September 30, 2019 and 2018, respectively. The decrease in the effective income tax rate was primarily attributable to the Company’s discrete tax benefits of $1.5 million and $0.9 million in relation to income before income taxes of $31.9 million and $38.0 million for the three months ended September 30, 2019 and 2018, respectively. We currently estimate our annual effective tax rate to be approximately 24% for 2019. The 26% effective tax rate for the three months ended September 30, 2019 differs from our estimated annual effective tax rate of 24% primarily due to less proportionate discrete tax benefits recorded during the three months ended September 30, 2019, as compared to the nine months ended September 30, 2019, in relation to income before income taxes. The discrete tax benefits are related to equity awards vested and exercised and fair value changes in the cash surrender value of our Company Owned Life Insurance (“COLI”) and reductions to the reserve for unrecognized tax benefits.

### Comparison of Results for the Nine Months Ended September 30, 2019 to the Nine Months Ended September 30, 2018

***Revenue.*** Revenue increased 2% to $1,635.2 million for the nine months ended September 30, 2019 from $1,607.4 million for the same period in 2018, primarily attributable to additional revenue of $76.7 million from our PDA, LFT, MedPartners, Silversheet, and Advanced acquisitions and higher organic revenue in our nurse and allied solutions segment, partially offset by an approximately $8.0 million decrease in labor disruption revenue and lower revenue in our locum tenens solutions segment. Excluding the additional revenue from acquisitions, revenue decreased 3%.

Nurse and allied solutions segment revenue increased 6% to $1,031.2 million for the nine months ended September 30, 2019 from $977.2 million for the same period in 2018. The $54.0 million increase was primarily attributable to additional revenue of $41.7 million in connection with the Advanced acquisition and a 1% increase in the average number of healthcare professionals on assignment during the nine months ended September 30, 2019, partially offset by an approximately $8.0 million decrease in labor disruption revenue.

Locum tenens solutions segment revenue decreased 21% to $246.7 million for the nine months ended September 30, 2019 from $311.5 million for the same period in 2018. The $64.8 million decrease was primarily attributable to a 21% decrease in the number of days filled during the nine months ended September 30, 2019, partially offset by a slight increase in the revenue per day filled.

Other workforce solutions segment revenue increased 12% to $357.3 million for the nine months ended September 30, 2019 from $318.7 million for the same period in 2018. Of the $38.6 million increase, $35.1 million was attributable to additional revenue in connection with the PDA, LFT, MedPartners, and Silversheet acquisitions, with the remainder primarily attributable to growth in our permanent placement, recruitment process outsourcing, VMS, and organic interim leadership businesses, partially offset by a decline in our organic revenue cycle solutions business during the nine months ended September 30, 2019.

***Gross Profit.*** Gross profit increased 4% to $546.3 million for the nine months ended September 30, 2019 from $523.9 million for the same period in 2018, representing gross margins of 33.4% and 32.6%, respectively. The gross margin for the nine months ended September 30, 2019 was positively impacted by a higher gross margins in our nurse and allied solutions segment, driven by higher labor disruption margin, higher other workforce solutions gross margin, a change in our physician permanent placement business model that prompted a $4.3 million classification of certain recruiter compensation expenses to SG&A that was previously in cost of revenue, and a favorable segment mix shift. These positive factors were partially offset by a lower margin in our locum tenens solutions segment. Gross margin by reportable segment for the nine months ended September 30, 2019 and 2018 was 27.8% and 27.2% for nurse and allied solutions, 27.7% and 29.0% for locum tenens solutions, and 53.7% and 52.6% for other workforce solutions, respectively. The year-over-year gross margin decline in the locum tenens solutions segment was driven by lower perm conversion fees and lower bill-to-pay spreads.

***Selling, General and Administrative Expenses.*** SG&A expenses were $374.9 million, representing 22.9% of revenue, for the nine months ended September 30, 2019, as compared to $341.5 million, representing 21.2% of revenue, for the same period in 2018. The increase in SG&A expenses was primarily due to $17.8 million of additional SG&A expenses from the PDA, LFT, MedPartners, Silversheet and Advanced acquisitions, a $17.3 million increase related to acquisition, integration, changes in the fair value of earn-out liabilities from acquisitions, and extraordinary legal expenses, a $3.8 million increase in share-based compensation expense, and higher employee compensation expenses. The increase was partially offset by an additional $3.5 million of favorable actuarial-based decreases in our professional liability reserves as compared to the same period in 2018 and a $12.1 million increase in legal accruals during the nine months ended September 30, 2018. SG&A expenses broken down among the reportable segments, unallocated corporate overhead, and share-based compensation are as follows:

|  | (In Thousands) Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Nurse and allied solutions | $142,196 | $128,107 |
| Locum tenens solutions | 49,281 | 55,930 |
| Other workforce solutions | 110,589 | 90,226 |
| Unallocated corporate overhead | 61,093 | 59,271 |
| Share-based compensation | 11,713 | 7,954 |
|  | $374,872 | $341,488 |

***Depreciation and Amortization Expenses.*** Amortization expense increased 44% to $25.4 million for the nine months ended September 30, 2019 from $17.6 million for the same period in 2018, with the increase primarily attributable to additional amortization expenses related to the intangible assets acquired in the PDA, LFT, MedPartners, Silversheet and Advanced acquisitions and the shortened useful life of the tradename intangible asset acquired in the MedPartners acquisition. Depreciation expense increased 32% to $16.1 million for the nine months ended September 30, 2019 from $12.2 million for the same period in 2018, primarily attributable to an increase in purchased and developed hardware and software placed in service for our ongoing front and back office information technology initiatives.

***Interest Expense, Net, and Other.*** Interest expense, net, and other, was $19.6 million during the nine months ended September 30, 2019 as compared to $16.4 million for the same period in 2018. The increase is primarily due to a higher average debt outstanding balance for the nine months ended September 30, 2019, which resulted from borrowings used to finance the Silversheet and Advanced acquisitions, and a $1.4 million gain related to the change in fair value of an equity investment during the nine months ended September 30, 2018. The overall increase is partially offset by higher income from restricted investments related to our captive insurance company for the nine months ended September 30, 2019.

***Income Tax Expense.*** Income tax expense was $23.9 million for the nine months ended September 30, 2019 as compared to income tax expense of $30.2 million for the same period in 2018, reflecting effective income tax rates of 22% and 22% for these periods, respectively. We currently estimate our annual effective income tax rate to be approximately 24% for 2019. The 22% effective tax rate for the nine months ended September 30, 2019 differs from our estimated annual effective income tax rate of 24% due to lower income before income taxes for the nine months ended September 30, 2019 compared to projected income before income taxes for the twelve months ended December 31, 2019 in proportion to the same amount of discrete tax benefits for both periods.

### Liquidity and Capital Resources

In summary, our cash flows were:

|  | (In Thousands) Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $146,205 | $168,046 |
| Net cash used in investing activities | (253,606) | (271,648) |
| Net cash provided by financing activities | 136,440 | 81,774 |

Historically, our primary liquidity requirements have been for acquisitions, working capital requirements, and debt service under our credit facilities and senior notes. We have funded these requirements through internally generated cash flow and funds borrowed under our credit facilities. As of September 30, 2019, (1) the total of our Term Loan (as defined below) outstanding (including both current and long-term portions) was $149.1 million, (2) $146.0 million was drawn with $239.3 million of available credit under the Senior Credit Facility (as defined below), and (3) the aggregate principal amount of our 5.125% Senior Notes due 2024 (the “2024 Notes”) outstanding equaled $325.0 million. We describe in further detail our credit agreement, in effect prior to the amendment thereof, under which our Senior Credit Facility is governed, and the 2024 Notes in “Item 8. Financial Statements and Supplementary Data—Notes to Consolidated Financial Statements—Note (7), Notes Payable and Credit Agreement” of our 2018 Annual Report on Form 10-K. See additional information on our Amended Credit Agreement (as defined below) in Note (6), “Notes Payable and Credit Agreement” to the accompanying Condensed Consolidated Financial Statements.

We believe that cash generated from operations and available borrowings under our Senior Credit Facility will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond. We intend to finance potential future acquisitions with cash provided from operations, borrowings under our Senior Credit Facility or other borrowings under our Amended Credit Agreement, bank loans, debt or equity offerings, or some combination of the foregoing. The following discussion provides further details of our liquidity and capital resources.

### Operating Activities

Net cash provided by operating activities for the nine months ended September 30, 2019 was $146.2 million, compared to $168.0 million for the same period in 2018. The decrease in net cash provided by operating activities was primarily attributable to a decrease in accounts payable and accrued expenses primarily due to payment of a loss contingency during the second quarter of 2019 and increases in subcontractor receivables, income tax receivable, and other assets. The overall decrease was partially offset by a decrease in accounts receivable and increases in accrued compensation and benefits and other liabilities between periods due to timing of payments. Our Days Sales Outstanding (“DSO”) was 57 days at September 30, 2019, 64 days at December 31, 2018, and 64 days at September 30, 2018.

### Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2019 was $253.6 million, compared to $271.6 million for the same period in 2018. The decrease was primarily due to net proceeds of restricted investments related to our captive insurance company of $11.9 million during the nine months ended September 30, 2019, as compared to a net purchase of $16.8 million during the nine months ended September 30, 2018. The decrease was partially offset by $228.2 million used for acquisitions during the nine months ended September 30, 2019, as compared to $217.4 million used for acquisitions during the nine months ended September 30, 2018. See additional information in the accompanying Note (2),

“Acquisitions.” Capital expenditures were $24.8 million and $23.9 million for the nine months ended September 30, 2019 and 2018, respectively.

### Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2019 was $136.4 million, primarily due to borrowings of $101.0 million under the Senior Credit Facility (as defined below) and $150.0 million of borrowings under the Term Loan (as defined below) used to fund our Advanced acquisition, partially offset by (1) the repayment of $75.0 million under the Senior Credit Facility, (2) $18.7 million paid in connection with the repurchase of our common stock, (3) $5.7 million for acquisition contingent consideration earn-out payments, and (4) $13.3 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards. Net cash provided by financing activities during the nine months ended September 30, 2018 was $81.8 million, primarily due to borrowings of $195.0 million under the Senior Credit Facility, partially offset by (1) the repayment of $45.0 million under the Senior Credit Facility, (2) $52.8 million paid in connection with the repurchase of common stock, (3) $2.3 million payment of financing costs in connection with the new credit agreement, (4) $1.7 million for acquisition contingent consideration earn-out payments, and (5) $11.4 million in cash paid for shares withheld for payroll taxes resulting from the vesting of employee equity awards.

### Amended Credit Agreement

On February 9, 2018, we entered into a credit agreement (the “New Credit Agreement”) with several lenders to provide for a $400.0 million secured revolving credit facility (the “Senior Credit Facility”) to replace our then-existing credit agreement. The Senior Credit Facility includes a $50.0 million sublimit for the issuance of letters of credit and a $50.0 million sublimit for swingline loans. On June 14, 2019, we entered into the first amendment to the New Credit Agreement (the “First Amendment”) to provide for, among other things, a $150.0 million secured term loan credit facility (the “Term Loan” and, together with the Senior Credit Facility, the “Credit Facilities”). The First Amendment (together with the New Credit Agreement, the “Amended Credit Agreement”) also extended the maturity date of the Senior Credit Facility to be coterminous with the Term Loan. Our obligations under the Amended Credit Agreement are secured by substantially all of our assets. For more detail regarding the terms of the Amended Credit Agreement, including maturity dates, payment and interest terms, please see Note (6) to the accompanying Condensed Consolidated Financial Statements, “Notes Payable and Credit Agreement.”

### Letters of Credit

At September 30, 2019, we maintained outstanding standby letters of credit totaling $17.1 million as collateral in relation to our workers’ compensation insurance agreements and a corporate office lease agreement. Of the $17.1 million of outstanding letters of credit, we have collateralized $2.3 million in cash and cash equivalents and the remaining $14.8 million is collateralized by the Senior Credit Facility. Outstanding standby letters of credit at December 31, 2018 totaled $17.6 million.

### 4.625% Senior Notes Due 2027

On October 1, 2019, AMN Healthcare, Inc. (the “Issuer”), a wholly owned subsidiary of AMN Healthcare Services, Inc. (the “Parent”), completed the issuance of $300.0 million aggregate principal amount of 4.625% Senior Notes due 2027 (the “2027 Notes”). The 2027 Notes will mature on October 1, 2027. Interest on the 2027 Notes is payable semi-annually in arrears on April 1 and October 1 of each year, commencing April 1, 2020.

The 2027 Notes were issued pursuant to an Indenture (the “Indenture”), dated as of October 1, 2019, by and among the Issuer, the Parent, the subsidiary guarantors party thereto (collectively, together with the Parent, the “Guarantors”) and U.S. Bank National Association, as trustee, and are senior unsecured obligations of the Issuer. The Guarantors have guaranteed (the “Guarantees”) the Issuer’s obligations under the 2027 Notes and the Indenture on a senior unsecured basis. The Guarantors include the Parent and the subsidiaries of the Issuer that guarantee the Issuer’s Credit Facilities.

The 2027 Notes will rank *pari passu* in right of payment with all of the Issuer’s existing and future senior indebtedness, senior to all of the Issuer’s existing and future subordinated indebtedness and effectively subordinated to all of the Issuer’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness.

The Guarantees will be each Guarantor’s senior unsecured obligations and will rank *pari passu* in right of payment with all of such Guarantor’s existing and future senior indebtedness, senior to all of such Guarantor’s existing and future subordinated indebtedness and effectively subordinated to all of such Guarantor’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness.

The 2027 Notes and the Guarantees will be structurally subordinated to all existing and future indebtedness and other liabilities and preferred stock of any of the Issuer’s subsidiaries that do not guarantee the 2027 Notes.

At any time and from time to time on and after October 1, 2022, the Issuer will be entitled at its option to redeem all or a portion of the 2027 Notes upon not less than 30 nor more than 60 days’ notice, at the redemption prices (expressed in percentages of principal amount on the redemption date) set forth below, plus accrued and unpaid interest, if any, to (but excluding) the redemption date (subject to the right of holders of record of the 2027 Notes on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the twelve month period commencing on October 1 of the years set forth below:

| Period | Redemption Price |
| --- | ---: |
| 2022 | 102.313% |
| 2023 | 101.156% |
| 2024 and thereafter | 100.000% |

At any time and from time to time prior to October 1, 2022, the Issuer may also redeem 2027 Notes with the net cash proceeds of certain equity offerings in an aggregate principal amount not to exceed 40% of the aggregate principal amount of the 2027 Notes issued, at a redemption price (expressed as a percentage of principal amount) of 104.625% of the principal amount thereof plus accrued and unpaid interest, if any, to (but excluding) the applicable redemption date.

In addition, the Issuer may redeem some or all of the 2027 Notes at any time and from time to time prior to October 1, 2022 at a redemption price equal to 100% of the principal amount of the 2027 Notes redeemed, plus accrued and unpaid interest thereon, if any, to (but excluding) the applicable redemption date, plus a “make-whole” premium based on the applicable treasury rate plus 50 basis points.

Upon the occurrence of specified change of control events as defined in the Indenture, the Issuer must offer to repurchase the 2027 Notes at 101% of the principal amount, plus accrued and unpaid interest, if any, to (but excluding) the purchase date.

The Indenture contains covenants that, among other things, restrict the ability of the Parent, the Issuer, and their restricted subsidiaries to:

- sell assets,
- pay dividends or make other distributions on capital stock, make payments in respect of subordinated indebtedness or make other restricted payments,
- make certain investments,
- incur or guarantee additional indebtedness or issue preferred stock,
- create certain liens,
- enter into agreements that restrict dividends or other payments from restricted subsidiaries’ to the Issuer, the Parent or their restricted subsidiaries,
- consolidate, merge or transfer all or substantially all of their assets,
- enter into transactions with affiliates, and
- create unrestricted subsidiaries.

These covenants are subject to a number of important exceptions and qualifications. The Indenture contains affirmative covenants and events of default that are customary for Indentures governing high yield securities. The 2027 Notes and the Guarantees are not subject to any registration rights agreement.

We used the proceeds from the issuance of the 2027 Notes to (1) repay $149.1 million of our existing Term Loan indebtedness, (2) repay $146.0 million under the Senior Credit Facility, and (3) pay fees and expenses related to the offering and sale of the 2027 Notes.

### Off-Balance Sheet Arrangements

At September 30, 2019, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

### Contractual Obligations

There have been no material changes during the nine months ended September 30, 2019, other than the borrowings under the New Credit Agreement and Amended Credit Agreement described in the accompanying Note (2), “Acquisitions” and Note (6), “Notes Payable and Credit Agreement,” to the table entitled “Contractual Obligations” in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” set forth in our 2018 Annual Report.

### Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments.” The standard introduces new accounting models for determining and recognizing credit losses on certain financial instruments based on an estimate of current expected credit losses and is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We are in the process of analyzing the requirements of this standard and evaluating the impact on our consolidated financial statements. This includes reviewing current accounting policies and practices to identify potential differences that would result from applying the requirements under the new standard. We completed our preliminary assessment and expect to complete the evaluation of the impact of the accounting and disclosure requirements on our business processes, controls and systems by the end of 2019. We will adopt this standard in the first quarter of 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the subsequent measurement of goodwill by removing the requirement to perform a hypothetical purchase price allocation to compute the implied fair value of goodwill to measure impairment. Instead, any goodwill impairment will equal the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Further, the guidance eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. This standard is effective for annual or any interim goodwill impairment test in fiscal years beginning after December 15, 2019, with early adoption permitted for impairment tests performed after January 1, 2017. We will adopt this standard in the first quarter of 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.” The standard modifies the current disclosure requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We will adopt this standard in the first quarter of 2020 and are currently evaluating the effect that adopting it will have on our disclosures.

In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” The standard aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The new guidance requires the capitalized implementation costs to be recorded as an other asset, rather than a fixed asset, and the related amortization of those costs to be recorded in selling, general and administrative expenses. This standard is effective on a prospective or retrospective basis for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. We will adopt this standard prospectively in the first quarter of 2020 and do not expect the adoption to have a material impact on our consolidated financial statements.

There have been no other new accounting pronouncements issued but not yet adopted that are expected to materially affect our consolidated financial condition or results of operations.

### Special Note Regarding Forward-Looking Statements

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We base these forward-looking statements on our expectations, estimates, forecasts, and projections about future events and about the industry in which we operate. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “should,” “would,” “project,” “may,” variations of such words, and other similar expressions. In addition, any statements that refer to projections of financial items, anticipated growth, future growth and revenues, future economic conditions and performance, plans, objectives and strategies for future operations, expectations, or other characterizations of future events or circumstances are forward-looking statements. All forward-looking statements involve risks and uncertainties. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Factors that could cause actual results to differ materially from those implied by the forward-looking statements in this Quarterly Report are set forth in our 2018 Annual Report and include but are not limited to:

- the effects of economic downturns or slow recoveries, which could result in less demand for our services and pricing pressures;
- any inability on our part to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs;
- the negative effects that intermediary organizations may have on our ability to secure new and profitable contracts with our clients;
- the level of consolidation and concentration of buyers of healthcare workforce solutions and staffing services, which could affect the pricing of our services and our ability to mitigate concentration risk;
- the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting or otherwise, which may negatively affect our revenue, results of operations, and cash flows;
- the repeal or significant erosion of the Patient Protection and Affordable Care Act without a corresponding replacement may negatively affect the demand for our services;
- any inability on our part to grow and operate our business profitably in compliance with federal and state healthcare industry regulation, including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding employment and compensation practices and government contracting;
- any challenge to the classification of certain of our healthcare professionals as independent contractors, which could adversely affect our profitability;
- any inability on our part to recruit and retain sufficient quality healthcare professionals at reasonable costs, which could increase our operating costs and negatively affect our business and profitability;
- the effect of investigations, claims, and legal proceedings alleging medical malpractice, violations of employment, privacy and wage regulations and other legal theories of liability asserted against us, which could subject us to substantial liabilities;
- any technology disruptions or our inability to implement new infrastructure and technology systems effectively may adversely affect our operating results and ability to manage our business effectively;
- any failure to further develop and evolve our current workforce solutions technology offerings and capabilities, which may harm our business;
- disruption to or failures of our SaaS-based technology or our inability to adequately protect our intellectual property rights with respect to such technology, which could reduce client satisfaction, harm our reputation and negatively affect our business;
- security breaches and cybersecurity incidents that could compromise our information and systems, which could adversely affect our business operations and reputation and could subject us to substantial liabilities;
- any inability on our part to quickly and properly credential and match quality healthcare professionals with suitable placements, which may adversely affect demand for our services;
- any inability on our part to continue to attract, develop and retain our sales and operations team members, which may deteriorate our operations;
- our increasing dependence on third parties for the execution of certain critical functions;
- the loss of our key officers and management personnel, which could adversely affect our business and operating results;
- any inability to consummate and effectively incorporate acquisitions into our business operations, which may adversely affect our long-term growth and our results of operations;
- businesses we acquire may have liabilities or adverse operating issues, which could harm our operating results;
- any increase to our business and operating risks as we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of client solutions;
- any inability on our part to maintain our positive brand awareness and identity, which may adversely affect our results of operation;
- the expansion of social media platforms presents new risks and challenges, which could cause damage to our brand reputation;
- any recognition of an impairment to the substantial amount of goodwill or indefinite-lived intangibles on our balance sheet;
- our indebtedness, which could adversely affect our ability to raise additional capital to fund operations, limit our ability to react to changes in the economy or our industry, and expose us to interest rate risk to the extent of any variable rate debt;
- the terms of our debt instruments that impose restrictions on us that may affect our ability to successfully operate our business; and
- the effect of significant adverse adjustments to our insurance-related accruals on our balance sheet, which could decrease our earnings or increase our losses and negatively impact our cash flows.

## Market risk

As filed, 1,072 characters.

Market risk is the risk of loss arising from adverse changes in market rates and prices, such as interest rates, foreign currency exchange rates, and commodity prices. During the three and nine months ended September 30, 2019, our primary exposure to market risk was interest rate risk associated with our variable interest debt instruments. A 100 basis point increase in interest rates on our variable rate debt would not have resulted in a material effect on our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2019. On October 1, 2019, we completed the issuance of $300.0 million aggregate principal amount of the 2027 Notes. With the proceeds from the issuance of the 2027 Notes, we repaid the full existing balance under the Senior Credit Facility and the full outstanding balance under the term loan indebtedness. During the three and nine months ended September 30, 2019, we generated substantially all of our revenue in the United States. Accordingly, we believe that our foreign currency risk is immaterial.

## Controls and procedures

As filed, 1,207 characters.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 2019 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 135 characters.

We do not believe that there have been any material changes to the risk factors disclosed in Part I, Item 1A of our 2018 Annual Report.

Filed Nov 4, 2019.
Source: SEC EDGAR, the filing index for accession 0001142750-19-000035. Last ingested by Listed: Nov 5, 2026, 17:59 ET. No prices; not investment advice.
